Company news
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news
Ionis Pharmaceuticals, Inc. news releases on 6ix. Latest, Apr 25, 2024: Ionis Publishes 2023 Corporate Responsibility Report
Press releases — page 3
Ionis Publishes 2023 Corporate Responsibility Report
April 24, 2024
Ionis to hold first quarter 2024 financial results webcast
April 22, 2024
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
April 6, 2024
Ionis to hold olezarsen Phase 3 data webcast
March 27, 2024
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
March 24, 2024
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
March 12, 2024
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
February 28, 2024
Ionis reports fourth quarter and full year 2023 financial results
February 20, 2024
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
February 14, 2024
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
February 7, 2024
Ionis to hold fourth quarter and full year 2023 financial results webcast
February 6, 2024
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
January 21, 2024
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
January 7, 2024
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
December 20, 2023
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
December 17, 2023
Ionis announces the appointment of Michael Yang to Board of Directors
December 13, 2023
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
November 10, 2023
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
November 8, 2023
Ionis reports third quarter 2023 financial results
November 1, 2023
Ionis to hold third quarter 2023 financial results webcast
October 18, 2023
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
October 3, 2023
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
September 27, 2023
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
September 26, 2023
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
September 25, 2023
Ionis to host investor and analyst day event
September 11, 2023
Ionis reports second quarter 2023 financial results
August 8, 2023
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
August 2, 2023
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
July 30, 2023
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
July 27, 2023
Ionis to hold second quarter 2023 financial results webcast
July 25, 2023
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
July 9, 2023
Ionis to present at upcoming investor conference
July 4, 2023
Ionis prices private placement of convertible senior notes
June 6, 2023
Ionis announces proposed private placement of convertible notes
June 5, 2023
Ionis announces positive donidalorsen late-stage clinical progress in HAE
May 31, 2023
Ionis to host 2023 virtual Annual Meeting of Stockholders
May 9, 2023
Ionis reports first quarter 2023 financial results
May 2, 2023
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
April 24, 2023
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
April 23, 2023
Ionis to hold first quarter 2023 financial results webcast
April 19, 2023
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
March 28, 2023
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
March 26, 2023
Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
March 21, 2023
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
March 6, 2023
Ionis reports fourth quarter and full year 2022 financial results
February 21, 2023
Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 20, 2023
Ionis to hold fourth quarter and full year 2022 financial results webcast
February 7, 2023
Ionis announces GSK has advanced bepirovirsen into Phase 3 development
January 31, 2023
Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
January 30, 2023